Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* B-CLL (CD23+, CD5+, CD19+, CD20+)~* Treatment indication according to NCI criteria~* Age \>= 18 yrs~* No previous treatment of CLL by chemo-, radio- or immunotherapy~* Life expectancy \> 6 months~* Written informed consent~* Women of non-childbearing potential or women of childbearing potential and men using effective contraception~Exclusion Criteria:~* Active bacterial, viral or fungal infection~* Positivity for HIV, Hepatitis B or C~* Reduce organ functions and bone marrow dysfunction not due to CLL~* Creatinine clearance below 30 ml/min~* Patients with medical conditions requiring long-term use of systemic corticosteroids during study treatment~* Patients with a history of severe cardiac disease~* Other known co-morbidity with the potential to dominate survival~* Transformation to aggressive B-cell malignancy~* Known hypersensitivity to humanised monoclonal antibodies or any of the study drugs~* Pregnant or breast-feeding women~* Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).